MedBiquitous

On July 9, the US Food and Drug Administration (FDA) released its Risk Evaluation and Mitigation Strategy or REMS for extended-release and long-acting (ER/LA) opioid analgesics.

The centerpiece of the ER/LA Opioid Analgesic...

Presentation about CE's role in ER/LA Opioid Analgesics REMS

The ...

Last Revised:
August 27, 2012

The ACCME views the FDA ER/LA Opioid Analgesic  REMS as an important initiative for addressing  a critical public health and patient safety concern. The ACCME believes that accredited CME can be an important factor in the success...